User:Mr. Ibrahem/Molnupiravir
 | |
| Clinical data | |
|---|---|
| Trade names | Lagevrio, Molulife , Molena, others[1] |
| Other names | MK-4482, EIDD-2801 |
| License data |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C13H19N3O7 |
| Molar mass | 329.309 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Molnupiravir, sold under the brand names Lagevrio and Molulife among others, is an antiviral used to treat COVID-19.[1] It has been found to be useful in mild but not severe disease.[6] It is used within 5 days of the start of symptom in those at risk of developed severe disease.[1] It is not; however, a preferred treatment.[7] It is taken by mouth.[1]
Common side effects include diarrhea, nausea, dizziness, and headache.[1] Safety in pregnancy is unclear.[1] The dose does not need to be adjusted in kidney or liver disease.[1] Use is not recommended in those under 18 due to concerns regarding effects on bone and cartilage.[3] It is metabolized within the body to ribonucleoside triphosphate (NHC-TP) which results in viral error catastrophe (large numbers of viral mutations).[1][3]
Molnupiravir was approved for medical use in the United Kingdom in November 2021.[1] In December 2021, it was granted an emergency use authorization (EUA) in the United States.[3] The recommendation for EUA approval was 13 to 10 with concerns regarding efficacy and that its mutagenic effects could create new variants.[8][9] In the United States a course of treatment costs about 700 USD while this amount in the developing world is about 20 USD as of 2022.[10]
References[edit]
- ^ a b c d e f g h i j k l m "Summary of Product Characteristics for Lagevrio". Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Archived from the original on 4 November 2021. Retrieved 4 November 2021.
- ^ "Regulatory approval of Lagevrio (molnupiravir)". Medicines and Healthcare products Regulatory Agency (MHRA). 4 November 2021. Archived from the original on 4 November 2021. Retrieved 4 November 2021.
- ^ a b c d "Molnupiravir capsule". DailyMed. Archived from the original on 5 January 2022. Retrieved 4 January 2022.
- ^ "Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults". U.S. Food and Drug Administration (FDA) (Press release). 23 December 2021. Archived from the original on 23 December 2021. Retrieved 23 December 2021.
This article incorporates text from this source, which is in the public domain.
- ^ "Archive copy". Archived from the original on 2021-12-23. Retrieved 2022-01-05.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Singh, Awadhesh Kumar; Singh, Akriti; Singh, Ritu; Misra, Anoop (November 2021). "Molnupiravir in COVID-19: A systematic review of literature". Diabetes & Metabolic Syndrome. 15 (6): 102329. doi:10.1016/j.dsx.2021.102329. ISSN 1878-0334. PMC 8556684. PMID 34742052.
- ^ "Statement on Therapies for High-Risk, Nonhospitalized Patients". COVID-19 Treatment Guidelines. Archived from the original on 7 January 2022. Retrieved 6 January 2022.
- ^ Kimball, Spencer (30 November 2021). "FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions". CNBC. Archived from the original on 1 January 2022. Retrieved 1 January 2022.
- ^ "A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm". www.science.org. Archived from the original on 23 December 2021. Retrieved 24 December 2021.
- ^ "Dr Reddy's to launch generic COVID-19 Merck drug at about 50 cents a pill". Reuters. 4 January 2022. Archived from the original on 5 January 2022. Retrieved 6 January 2022.
